| scholarly article | Q13442814 |
| P50 | author | Louis J. Aronne | Q6686665 |
| Caroline M. Apovian | Q54032792 | ||
| P2093 | author name string | Leon I Igel | |
| Amanda G Powell | |||
| P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Prevalence and trends in obesity among US adults, 1999-2008 | Q29547759 | ||
| Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial | Q30499944 | ||
| Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr | Q33279692 | ||
| Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials | Q77649542 | ||
| A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials | Q33874163 | ||
| Pramlintide and the treatment of diabetes: a review of the data since its introduction | Q33896433 | ||
| XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients | Q33974818 | ||
| Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database | Q34016012 | ||
| The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. | Q34339578 | ||
| Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial | Q34361001 | ||
| Meta-analysis: pharmacologic treatment of obesity | Q34408897 | ||
| Obesity and disease management: effects of weight loss on comorbid conditions | Q34438259 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| Multicenter, placebo-controlled trial of lorcaserin for weight management | Q34660152 | ||
| The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial | Q35111527 | ||
| The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review | Q35800117 | ||
| Drug treatment of the overweight patient | Q36820209 | ||
| Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity | Q36842060 | ||
| Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue | Q37337256 | ||
| Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy | Q37368085 | ||
| Pharmacologic therapies for obesity | Q37702546 | ||
| Weight Management in Type 2 Diabetes Mellitus | Q37801634 | ||
| Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial | Q42950914 | ||
| Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial | Q42977455 | ||
| Gastrointestinal hormones and weight management | Q43255698 | ||
| Annual medical spending attributable to obesity: payer-and service-specific estimates | Q44104253 | ||
| Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial | Q44333538 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. | Q45140920 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study | Q46357275 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group | Q47244827 | ||
| Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study | Q47288123 | ||
| Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes | Q47333592 | ||
| Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial | Q47381748 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. | Q51569984 | ||
| Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. | Q51586347 | ||
| Orlistat in the long-term treatment of obesity in primary care settings | Q73490701 | ||
| P433 | issue | 1 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 60-69 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Current Atherosclerosis Reports | Q20821076 |
| P1476 | title | Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus | |
| P478 | volume | 14 |
| Q57961571 | Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry |
| Q39873298 | Changes in Body Weight Among People With Type 2 Diabetes Mellitus in the United States, NHANES 2005-2012. |
| Q37316440 | Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications |
| Q38224376 | Systems analysis and the prediction and prevention of Type 2 diabetes mellitus |
| Q54490974 | Use of lorcaserin for glycemic control in patients with type 2 diabetes mellitus. |
| Q88766740 | Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction |
Search more.